<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560089</url>
  </required_header>
  <id_info>
    <org_study_id>C17-07</org_study_id>
    <nct_id>NCT03560089</nct_id>
  </id_info>
  <brief_title>Serious Games Rehabilitation Programme to Treat Gait and Balance Disorders in PD Patients</brief_title>
  <acronym>PARKGAME-II</acronym>
  <official_title>Serious Games Rehabilitation Programme to Treat Gant and Balance Disorders in Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the effects of a serious game rehabilitation programme in 50 patients with
      Parkinson's disease with gait and balance disorders in a randomised controlled study
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Blinded assessment of video</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of the time-up-go test</measure>
    <time_frame>change between baseline and at 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of the time-up-go test</measure>
    <time_frame>change between baseline and at 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step length</measure>
    <time_frame>change between baseline and at 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>step velocity</measure>
    <time_frame>change between baseline and at 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Movement disorders Unified Parkinson's disease rating scale</measure>
    <time_frame>change between baseline and at 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>freezing of gait questionnaire</measure>
    <time_frame>change between baseline and at 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's disease quality of life scale</measure>
    <time_frame>change between baseline and at 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gait and balance scale</measure>
    <time_frame>change between baseline and at 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment</measure>
    <time_frame>change between baseline and at 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic resonance imaging</measure>
    <time_frame>change between baseline and at 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Rehabilitation with active serious game</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 patients will perform motor rehabilitation programme using the serious game</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No active serious game</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>25 patients will not perform motor rehabilitation programme using the serious game</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Serious game</intervention_name>
    <description>Serious game with movements</description>
    <arm_group_label>Rehabilitation with active serious game</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo serious game</intervention_name>
    <description>Serious game without movement</description>
    <arm_group_label>No active serious game</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parkinson's disease

          -  Gait and balance disorders resistant to dopaminergic medication

        Exclusion Criteria:

          -  dementia

          -  contra-indication to magnetic resonance imaging
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Laure Welter, PH MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICM, 47 bd de l'Hôpital, 75013 Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Laure Welter, PH MD PHD</last_name>
    <phone>0142165777</phone>
    <email>marielaure.welter@icm-institute.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Laure WELTER, PH MD PHD</last_name>
    <phone>0142165777</phone>
    <email>marielaure.welter@icm-institute.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Investigation Clinique- ICM</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Laure Welter</last_name>
      <phone>+33142165777</phone>
      <email>marie-laure.welter@icm-institute.org</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>June 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>August 30, 2019</last_update_submitted>
  <last_update_submitted_qc>August 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Gait</keyword>
  <keyword>Rehabilitation</keyword>
  <keyword>Serious game</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

